{
    "organizations": [],
    "uuid": "78ac2432a0930b299a1efce9ef344d3c4549e393",
    "author": "",
    "url": "https://www.reuters.com/article/brief-beigene-initiates-global-phase-2-t/brief-beigene-initiates-global-phase-2-trial-of-anti-pd-1-antibody-tislelizumab-idUSASC09VWD",
    "ord_in_thread": 0,
    "title": "BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 06 AM / Updated 11 minutes ago BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab Reuters Staff 1 Min Read \nApril 16 (Reuters) - Beigene Ltd: \n* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-16T14:05:00.000+03:00",
    "crawled": "2018-04-16T14:21:01.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "initiate",
        "global",
        "phase",
        "trial",
        "antibody",
        "tislelizumab",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "initiate",
        "global",
        "phase",
        "trial",
        "antibody",
        "tislelizumab",
        "patient",
        "relapsed",
        "refractory",
        "mature",
        "lymphoma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}